BRPI1010283A2 - salmonella enterica apresentando n-glicano de c. jejuni ou derivados dos mesmo - Google Patents

salmonella enterica apresentando n-glicano de c. jejuni ou derivados dos mesmo

Info

Publication number
BRPI1010283A2
BRPI1010283A2 BRPI1010283A BRPI1010283A BRPI1010283A2 BR PI1010283 A2 BRPI1010283 A2 BR PI1010283A2 BR PI1010283 A BRPI1010283 A BR PI1010283A BR PI1010283 A BRPI1010283 A BR PI1010283A BR PI1010283 A2 BRPI1010283 A2 BR PI1010283A2
Authority
BR
Brazil
Prior art keywords
jejuni
glycan
derivatives
showing
enteric salmonella
Prior art date
Application number
BRPI1010283A
Other languages
English (en)
Inventor
Flavio Schwarz
Karin Ilg
Markus Aebi
Saba Amber
Umesh Ahuja
Original Assignee
Eidgenoess Tech Hochschule
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoess Tech Hochschule filed Critical Eidgenoess Tech Hochschule
Publication of BRPI1010283A2 publication Critical patent/BRPI1010283A2/pt
Publication of BRPI1010283B1 publication Critical patent/BRPI1010283B1/pt
Publication of BRPI1010283B8 publication Critical patent/BRPI1010283B8/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/105Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36Adaptation or attenuation of cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K2039/106Vibrio; Campylobacter; Not used, see subgroups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI1010283A 2009-03-27 2010-03-25 salmonella enterica apresentando n-glicano de c.jejuni ou derivados do mesmo, seu uso, método de produção e composição farmacêutica, alimento ou ração, aditivo alimentar ou de ração compreendendo a mesma BRPI1010283B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09004445 2009-03-27
EP09004445.4 2009-03-27
PCT/EP2010/001884 WO2010108682A1 (en) 2009-03-27 2010-03-25 Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof

Publications (3)

Publication Number Publication Date
BRPI1010283A2 true BRPI1010283A2 (pt) 2016-10-11
BRPI1010283B1 BRPI1010283B1 (pt) 2021-04-06
BRPI1010283B8 BRPI1010283B8 (pt) 2021-05-25

Family

ID=42199060

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1010283A BRPI1010283B8 (pt) 2009-03-27 2010-03-25 salmonella enterica apresentando n-glicano de c.jejuni ou derivados do mesmo, seu uso, método de produção e composição farmacêutica, alimento ou ração, aditivo alimentar ou de ração compreendendo a mesma

Country Status (14)

Country Link
US (2) US9309493B2 (pt)
EP (1) EP2411503B1 (pt)
JP (1) JP5568626B2 (pt)
KR (1) KR101395431B1 (pt)
CN (1) CN102365359B (pt)
BR (1) BRPI1010283B8 (pt)
CA (1) CA2757224C (pt)
ES (1) ES2646320T3 (pt)
IL (1) IL215239A (pt)
MX (1) MX2011009791A (pt)
PL (1) PL2411503T3 (pt)
PT (1) PT2411503T (pt)
RU (1) RU2507253C2 (pt)
WO (1) WO2010108682A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2501406T3 (en) * 2009-11-19 2018-02-26 Glaxosmithkline Biologicals Sa BIOSYNTHESE SYSTEM PRODUCING IMMUNOGENIC POLYSACCHARIDES IN PROCARYOTIC CELLS
US20140336366A1 (en) * 2011-09-06 2014-11-13 Glycovaxyn Ag Bioconjugate vaccines made in prokaryotic cells
CA2894795A1 (en) 2012-04-27 2013-10-31 The Governors Of The University Of Alberta Glycoengineered outer membrane vesicles and use thereof as vaccines
CA2907795C (en) 2013-04-05 2023-09-05 The Governors Of The University Of Alberta Campylobacter vaccine
CN103740632B (zh) * 2014-01-22 2016-02-10 山东大学 一株重组大肠杆菌及其在制备抗o157:h7的n-糖蛋白疫苗中的应用
US11000583B2 (en) 2017-01-27 2021-05-11 University Of Florida Research Foundation, Incorporated Food safety vaccine to control Salmonella enterica and reduce campylobacter in poultry
EP3595711A1 (en) 2017-03-15 2020-01-22 London School of Hygiene & Tropical Medicine Whole cell vaccines
PE20171768A1 (es) * 2017-06-12 2017-12-21 Farm Veterinarios S A C Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar
BR112020012553A2 (pt) * 2017-12-19 2020-11-24 The Governors Of The University Of Alberta glicanos de superfície de clostridium perfringens e usos dos mesmos
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399074B1 (en) * 1998-07-24 2002-06-04 Megan Health, Inc. Live attenuated salmonella vaccines to control avian pathogens
JP5016779B2 (ja) * 2001-05-03 2012-09-05 フィット バイオテク オーワイ 発現ベクターおよびその使用方法
WO2004013151A2 (en) * 2002-08-01 2004-02-12 National Research Council Of Canada Campylobacter glycans and glycopeptides
RU2237089C2 (ru) * 2002-10-31 2004-09-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантный аттенуированный штамм бактерий salmonella enteriditis е-23/pgex-2t-tbi как кандидат для конструирования живой вакцины против вируса иммунодефицита человека
BRPI0408774A (pt) * 2003-03-24 2006-03-28 Scripps Research Inst vacinas de dna contra crescimento tumoral e seus usos
RU2248396C2 (ru) * 2003-04-17 2005-03-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Рекомбинантная плазмидная днк pcdna-tci, обеспечивающая экспрессию искусственного гена tci в клетках эукариот, и рекомбинантный аттенуированный штамм бактерий salmonella enteritidis e-23/pcdna-tci как кандидат для конструирования живой днк-вакцины против вируса иммунодефицита человека
EP1655370A1 (en) * 2004-11-05 2006-05-10 Gesellschaft für Biotechnologische Forschung Bacterial vector
ES2353814T3 (es) * 2005-05-11 2011-03-07 Eth Zuerich Proteinas n-glicosiladas recombinantes de celulas procariotas.
WO2007038122A2 (en) 2005-09-21 2007-04-05 The United States Of America As Represented By The Secretary Of The Navy Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni
DE102008012452A1 (de) * 2008-03-04 2009-09-10 Tridonicatco Gmbh & Co. Kg Schaltung zum Beheizen und Überwachen der Heizwendeln mindestens einer mit einem elektronischen Vorschaltgerät betriebenen Gasentladungslampe auf Wendelbruch

Also Published As

Publication number Publication date
RU2011143381A (ru) 2013-05-10
CA2757224A1 (en) 2010-09-30
CA2757224C (en) 2016-12-06
MX2011009791A (es) 2011-10-17
ES2646320T3 (es) 2017-12-13
BRPI1010283B1 (pt) 2021-04-06
RU2507253C2 (ru) 2014-02-20
WO2010108682A1 (en) 2010-09-30
KR101395431B1 (ko) 2014-05-14
BRPI1010283B8 (pt) 2021-05-25
CN102365359B (zh) 2014-10-29
PT2411503T (pt) 2017-11-15
JP5568626B2 (ja) 2014-08-06
KR20110127714A (ko) 2011-11-25
EP2411503B1 (en) 2017-09-13
IL215239A0 (en) 2011-12-29
CN102365359A (zh) 2012-02-29
IL215239A (en) 2016-02-29
US20160213770A1 (en) 2016-07-28
EP2411503A1 (en) 2012-02-01
US9309493B2 (en) 2016-04-12
PL2411503T3 (pl) 2018-01-31
US9764021B2 (en) 2017-09-19
US20120100177A1 (en) 2012-04-26
JP2012521747A (ja) 2012-09-20

Similar Documents

Publication Publication Date Title
BRPI1010283A2 (pt) salmonella enterica apresentando n-glicano de c. jejuni ou derivados dos mesmo
BRPI1011459A2 (pt) embalagem de isolamento.
BR112013013584A2 (pt) endoscópio, e, método
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BRPI0913426A2 (pt) máquina de processamento de alimentos
BRPI1016079A2 (pt) escaneamento antivírus.
DK2288552T3 (da) Fødevareemballage
BRPI0911588A2 (pt) processamento de biomassa
BRPI0913059A2 (pt) processamento de biomassa
BRPI0921036A2 (pt) processamento de biomassa
BRPI1011134A2 (pt) turbomáquina.
BRPI0921987A2 (pt) processamento de biomassa
BRPI0813569A2 (pt) Método de inspeção.
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
DK2515662T3 (da) Kødforarbejdningsanlæg
BRPI0924081A2 (pt) DERIVADOS DE 5- AMINO -2-(1-hIDROXI-ETIL)- TETRAHIDROPIRANO.
BRPI0906714A2 (pt) Derivados de oxazepinopirimidona heteroarilamida substituídos.
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.
DE602007001605D1 (de) Tunnel-Pasteurisierer
BR112012000565A2 (pt) ensaio de vírus.
BRPI0922477A2 (pt) transportador.
BR112012004367A2 (pt) método de detecção de adulteração.
BR112012000262A2 (pt) composição farmacêutica, e, método de tratamento de uma condição.
BRPI1015429A2 (pt) máquina de embalagem, e, método de embalagem.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF